Global Cost-Effectiveness of Cardiac Resynchronization Therapy for Heart Failure

Eighteen studies from a systematic review up to July 2025 evaluate the cost-effectiveness of cardiac resynchronization therapy (CRT). The dataset, created by Kaltrina Bajraktari and last updated in May 2026, compiles economic outcomes like incremental cost-effectiveness ratios (ICERs) for CRT compared to standard medical therapy. Costs are standardized to 2024 euros and assessed against country-specific willingness-to-pay thresholds.

Use Cases

• Modeling the cost-effectiveness of CRT-P versus CRT-D based on reported ICER ranges.
• Benchmarking healthcare costs for heart failure interventions across different countries using standardized 2024 euros.
• Supporting health technology assessment (HTA) submissions with synthesized evidence from 18 studies.
• Analyzing the relationship between willingness-to-pay thresholds and treatment recommendations for heart failure.

Strengths

• Systematic review methodology with a registered PROSPERO protocol (CRD420251171292).
• Costs are standardized to a common currency (2024 euros) for cross-study comparison.
• Includes 18 studies identified from three major databases (Web of Science, PubMed, Scopus).

Limitations

• Row count and specific column-level documentation are unknown, requiring manual inspection after download.
• The dataset is small (53.9 KB), indicating a limited scope focused on summary-level review data.
• Freshness should be verified as the last update timestamp is in the future (2026-05-21).

Provenance

Source

figshare, author Kaltrina Bajraktari.

Collection Method

Systematic review of literature from Web of Science, PubMed, and Scopus (2004 to July 2025).

Time Range

Studies published from January 2004 up to July 2025.

Freshness

Last updated 2026-05-21 12:55:05; freshness should be verified.

Geography

Global evidence, with costs assessed against country-specific thresholds.